Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44])

The summary for the Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44]) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44])
	CFDA Number:	93.242
	CFDA Description:	Mental Health Research Grants
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-06-016
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Oct 20, 2005
	Creation Date:	Oct 20, 2005
	Original Closing Date for Applications:	Multiple dates, see announcement.
	Current Closing Date for Applications:	Information not provided
	Archive Date:	Oct 02, 2008
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Only United States small business concerns (SBCs) are eligible to submit SBIR applications. A small business concern is one that, at the time of award, for both Phase I and Phase II awards, meets all of the following criteria: 1. Is independently owned and operated, is not dominant in the field of operation in which it is proposing, has a place of business in the United States and operates primarily within the United States or makes a significant contribution to the US economy, and is organized for profit. 2. Is (a) at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, or (b) for SBIR only, it must be a for-profit business concern that is at least 51 percent owned and controlled by another for-profit business concern that is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States. 3. Has, including its affiliates, an average number of employees for the preceding 12 months not exceeding 500, and meets the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns are generally considered to be affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Control can be exercised through common ownership, common management, and contractual relationships. The term affiliates is defined in greater detail in 13 C.F.R. 121.103. The term number of employees is defined in 13 C.F.R. 121.106.
Grant Description: - This funding opportunity will utilize the Small Business Innovation Research (SBIR) mechanism, but will be run in parallel with a program announcement of identical scientific scope (RFA-DK-05-015) that will utilize the Small Business Technology Transfer (STTR) grant mechanism. - The National Institute of Diabetes, Digestive and Kidney diseases (NIDDK), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Child Health and Human development (NICHD) invite the small business community to apply cutting edge technology to investigate the development of new approaches to predict, prevent, treat, and cure type 1 Diabetes (T1D) and its complications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-06-016.html http://grants.nih.gov/grants/guide/pa-files/PA-06-016.html
Grant Announcement Contact: Webmaster, NIH, Webmaster, Phone not available, Fax not available, Email FBOWebmaster@mail.nih.gov FBOWebmaster@mail.nih.gov Webmaster, NIH
Similar Government Grants: • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R21); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R03); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R03); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R34); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R34); • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R42]); • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (STTR [R41/R42]); • Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Screening Cent...; • Competing Renewal Awards of SBIR Phase II Grants for Pharmacologic Agents and Drugs for Mental Disor...